טוען...
Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia
BACKGROUND: Imatinib is a highly effective treatment for chronic myeloid leukemia (CML) that was approved by the Food and Drug Administration in 2001, and thereafter rapidly became front line therapy. This study characterized the prevailing chronic myeloid leukemia therapies in the United States and...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2913144/ https://ncbi.nlm.nih.gov/pubmed/20670732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjmed.2010.03.018 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|